A report released today by N+1 Singer about Midatech Pharma Plc (LON:MTPH) holds the target price at 283.00GBX
- Updated: September 30, 2016
Boasting a price of 132.00GBX, Midatech Pharma Plc (LON:MTPH) traded 1.63% higher on the day. With the last stock price close down -12.06% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. MTPH has recorded a 50-day average of 145.06GBX and a two hundred day average of 141.57GBX. Volume of trade was up over the average, with 41,986 shares of MTPH changing hands over the typical 21,343
Midatech Pharma Plc (LON:MTPH) had its stock price target hold steady to 283.00GBX by N+1 Singer in a report released 09/30/2016. The new stock price target indicates a possible upside of 1.14% from the company's most recent stock price close.
On 9/21/2016, Panmure Gordon released a statement for Midatech Pharma Plc (LON:MTPH) maintained the target price at 380.00GBX that suggested an upside of 1.58%.
Recent Performance Chart
Midatech Pharma Plc has 52 week low of 100.51GBX and a 52 week high of 285.00GBX and has a market capitalization of 0 GBX.
In addition to N+1 Singer reporting its stock price target, a total of 2 brokers have issued a research note on the company. The average stock price target is 388.00GBX with 0 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Midatech Pharma Plc (LON:MTPH)
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.